Analyst Corner| Glenmark Pharma: ‘Buy’ with revised TP of Rs 488

By: |
Published: June 24, 2020 8:43 AM

Glenmark initially received DCGI nod to conduct phase-3 clinical trials with oral antiviral Favipiravir among COVID-19 patients in early May’20 and has now received manufacturing & marketing approval in India for treatment of mild to moderate COVID-19 patients.

Analyst Corner, Glenmark Pharma, oral antiviral Favipiravir, COVID-19,DCGI, COVID-19 patients, latest news on Glenmark PharmaGlenmark has launched it under its brand name ‘FabiFlu’ and is working with the government and medical community to make it accessible quickly.

Glenmark Pharmaceuticals (Glenmark) announced the receipt of regulatory approval to manufacture and market oral antiviral Favipiravir in India. It has been launched by Glenmark under the brand name ‘FabiFlu’ and is indicated for the treatment of mild to moderate COVID-19. This approval has been granted by DCGI under the accelerated approval process owing to the current precarious situation in India. Glenmark earlier received approval from DCGI for conducting clinical trials in India for Favipiravir in COVID-19 patients in early May and has now received marketing approval based on successful trials. Favipiravir showed clinical improvement of 88% in patients between age group of 20-90 years. This success reinforces company’s R&D capabilities and would provide decent financial upside. Maintain ‘BUY’.

Glenmark initially received DCGI nod to conduct phase-3 clinical trials with oral antiviral Favipiravir among COVID-19 patients in early May’20 and has now received manufacturing & marketing approval in India for treatment of mild to moderate COVID-19 patients. Glenmark has launched it under its brand name ‘FabiFlu’ and is working with the government and medical community to make it accessible quickly. This is a crucial success given deadly outbreak of COVID-19 in India. The sample included 150 subjects (90 mild and 60 moderate patients) in the age group of 20-90 years and improvements of up to 88% was seen. Glenmark has developed both the API and formulation in-house.
We maintain our estimates and raise target P/E(x) to 15x from 12x to factor in potential upside from Favipiravir and strong R&D capability. We maintain BUY rating with a revised target price of Rs488/share based on 15xFY22E EPS (earlier: Rs390/share). Downside risks: Regulatory hurdles and competitive pressures in the US.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Equity Strategy: Muted earnings were largely in line
2Markets rise 466 points to close at four-month high
3JP Morgan Funds buys TCS shares worth Rs 247 crore